Biomarker for Gangliosidosis: BioGM1 / BioGM2 (BioGM1/BioGM2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02298647
Recruitment Status : Not yet recruiting
First Posted : November 24, 2014
Last Update Posted : August 28, 2018
Information provided by (Responsible Party):
Centogene AG Rostock

Brief Summary:
Development of a new MS-based biomarker for the ear-ly and sensitive diagnosis of GM1/GM2 from blood

Condition or disease
Hepato-splenomegaly Dysostosis Multiplex Seizures Mental Retardation

  Show Detailed Description

Study Type : Observational
Estimated Enrollment : 1000 participants
Observational Model: Cohort
Time Perspective: Prospective
Estimated Study Start Date : August 20, 2018
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : July 2021

Patients with GM1/GM2-Gangliosidosis or high-grade suspicion for GM1/GM2-Gangliosidosis

Primary Outcome Measures :
  1. Development of a new MS-based biomarker for the early and sensitive diagnosis of GM1/GM2-Gangliosidosis from blood [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. Testing for clinical robustness, specificity and long-term stability of the biomarker [ Time Frame: 24 months ]

Biospecimen Retention:   Samples With DNA

For the development of the new biomarkers using the technique of Mass-spectometry, maximal 10 ml blood will be taken via using a dry blood spot filter card. To proof the cor-rect GM1/GM2 diagnosis in those patients where up to the enrollment into the study no genetic testing has been done, sequencing of GM1/GM2 will be done.

The analyses will be done at the Centogene AG Am Strande 7 18055 Rostock Germany

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   2 Months and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with GM1/GM2-Gangliosidosis or high-grade suspicion for GM1/GM2-Gangliosidosis


  • Informed consent will be obtained from the parents before any study related procedures.
  • Patients of both genders aged 2 months and older
  • The patient has a diagnosis of GM1/GM2-Gangliosidosis or a high-grade suspicion for GM1/GM2-Gangliosidosis
  • High-grade suspicion for GM1 or GM2 present, if one or more inclusion criteria are valid:

Positive family anamnesis for GM1 or GM2 disease

Neurodegenerative symptoms

Skeletal symptoms

Cherry Red Spot


  • No Informed consent from the parents before any study related procedures.
  • No diagnosis of GM1/GM2 disease or no valid criteria for profound suspicion of GM1/GM2 -disease
  • Patients of both genders younger than 2 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02298647

Contact: Anton Mamin, Dr. +49 381 80113 535
Contact: Volha Skrahina +49 381 80 113 594

Albrecht-Kossel-Institute for Neuroregeneration (AKos) Centre for Mental Health Disease University of Rostock Not yet recruiting
Rostock, Germany, 18147
Contact: Arndt Rolfs, Prof.    +49 381 494 ext 9540   
Sponsors and Collaborators
Centogene AG Rostock
Principal Investigator: Arndt Rolfs, Prof. Centogene AG Rostock

Additional Information:
Responsible Party: Centogene AG Rostock Identifier: NCT02298647     History of Changes
Other Study ID Numbers: BioGM1 / BioGM2
First Posted: November 24, 2014    Key Record Dates
Last Update Posted: August 28, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Centogene AG Rostock:

Additional relevant MeSH terms:
Intellectual Disability
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Neurobehavioral Manifestations
Neurodevelopmental Disorders
Mental Disorders
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders
Pathological Conditions, Anatomical
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases